Brock Davis
Kirksville, MONPI 1548909534
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.7% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations.
Across 163 payments — averaging $27.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$645
- E.r. Squibb & Sons, L.L.C.$483
- Lilly USA, LLC$390
- UCB, Inc.$385
- Sanofi$280
- Sun Pharmaceutical Industries Inc.$263
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,17994%
- Education$2796%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $645 |
| E.r. Squibb & Sons, L.L.C. | 17 | $483 |
| Lilly USA, LLC | 22 | $390 |
| UCB, Inc. | 15 | $385 |
| Sanofi | 8 | $280 |
| Sun Pharmaceutical Industries Inc. | 8 | $263 |
| Incyte Corporation | 5 | $231 |
| Regeneron Healthcare Solutions, Inc. | 6 | $220 |
| Janssen Scientific Affairs, LLC | 2 | $216 |
| Galderma Laboratories, L.p. | 3 | $181 |
| Arcutis Biotherapeutics, Inc. | 9 | $176 |
| Pfizer | 3 | $169 |
| Dermavant Sciences, Inc. | 2 | $136 |
| Novartis | 6 | $129 |
| Amgen | 6 | $114 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Eli Lilly | 1 | $99 |
| Genentech USA, Inc. | 3 | $58 |
| Johnson & Johnson | 3 | $55 |
| Viiv Healthcare Company | 2 | $35 |
| Mimedx Group, Inc. | 1 | $31 |
| Boehringer Ingelheim | 1 | $26 |
| Organon | 1 | $20 |
| Biofrontera Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 114 | $2,199 |
| Metronidazole | 25 | $1,687 |
| Fluocinonide | 14 | $731 |
| Ciclopirox | 21 | $620 |
| CiclopiroxCiclopirox Olamine | 15 | $613 |
| Doxycycline Hyclate | 16 | $386 |
| Triamcinolone Acetonide | 45 | $375 |
| Mupirocin | 48 | $328 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.